Atlas Trials

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

Clinical trial NCT01058642 · TERMINATED

Trial details

NCT number
NCT01058642
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Postherpetic Neuralgia
Start date
2010-01-01
Primary completion
2010-12-01
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.